EUVIMEDEUVIMED entdecken
Open Access

Next-generation therapy for lower-risk MDS

Marie Sébert

Hematology · 2023

DOI: 10.1182/hematology.2023000520 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hematology, 2023. Verfasst von Marie Sébert. Beteiligte Einrichtung: Saint-Louis Hospital (AP-HP) and Université de Paris Cité and INSERM U944, Paris, France. Hauptthemen laut MEDLINE: Myelodysplastic Syndromes, Anemia, Hematinics. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Myelodysplastic syndromes (MDS) are malignant myeloid neoplasms characterized by ineffective clonal hematopoiesis leading to peripheral blood cytopenia and a variable risk of transformation to acute myeloid leukemia. In lower-risk (LR) MDS, as defined by prognostic scoring systems recently updated with the addition of a mutation profile, therapeutic options aim to reduce cytopenia, mainly anemia. Although options for reducing the transfusion burden have recently been improved, erythropoiesis-stimulating agents (ESAs), lenalidomide, hypomethylating agents, and, more recently, luspatercept have shown efficacy in rarely more than 50% of patients with a duration of response often far inferior to the patient's life expectancy. Nevertheless, several new therapies are currently under investigation aiming at improving cytopenia in patients with LR-MDS, mostly by targeting different biological pathways. Targeting ligands of the transforming growth factor β pathway has led to the approval of luspatercept in LR-MDS with ring sideroblasts or SF3B1 mutation, potentially replacing first-line ESAs in this population. Here, we also discuss the evolving standard of care for the treatment of LR-MDS and explore some of the most promising next-generation agents under investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myelodysplastic SyndromesAnemiaHematinicsHumansLenalidomideHematopoiesis

Substanzen

LenalidomideHematinics

Autor:innen und Institutionen

  • Saint-Louis Hospital (AP-HP) and Université de Paris Cité and INSERM U944, Paris, France.

Zitieren

APA

Sébert, M. (2023). Next-generation therapy for lower-risk MDS. Hematology. https://doi.org/10.1182/hematology.2023000520

Vancouver

Sébert M. Next-generation therapy for lower-risk MDS. Hematology. 2023. doi:10.1182/hematology.2023000520

BibTeX
@article{Sbert2023,
  author = {Sébert, Marie},
  title = {Next-generation therapy for lower-risk MDS},
  journal = {Hematology},
  year = {2023},
  doi = {10.1182/hematology.2023000520}
}
Kostenlos starten →